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26 Abstract
27 Cardiovascular diseases are the leading causes of mortality. Sudden cardiac death is most 
28 commonly caused by ventricular fibrillation (VF). Atrial fibrillation (AF) is the most common 
29 sustained cardiac arrhythmia and a major cause of stroke and heart failure. Pharmacological 
30 management of VF and AF remains suboptimal due to limited efficacy of antiarrhythmic drugs 
31 and their ventricular proarrhythmic adverse effects. In this study, the antiarrhythmic and cardiac 
32 cellular electrophysiological effects of SZV-270, a novel compound, were investigated in rabbit 
33 and canine models. SZV-270 significantly reduced the incidence of VF in rabbits subjected to 
34 coronary artery occlusion/reperfusion, reduced the incidence of burst-induced AF in a 
35 tachypaced conscious canine model of AF. SZV-270 prolonged frequency corrected QT 
36 interval, lengthened action potential duration and effective refractory period in ventricular and 
37 atrial preparations and blocked IKr in isolated cardiomyocytes (Class III effects), reduced 
38 maximum rate of depolarization (Vmax) at cycle lengths smaller than 1000 ms in ventricular 
39 preparations (Class I/B effect). Importantly, SZV-270 did not provoke Torsades de Pointes 
40 arrhythmia in an anesthetized rabbit proarrhythmia model characterized by impaired 
41 repolarization reserve. In conclusion, SZV-270 with its combined Class I/B and III effects can 




46 action potential duration, atrial fibrillation, combined Class I/b and Class III effect, ventricular 
47 fibrillation, Torsades de Pointes
48
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49 List of abbreviations
50 AERP: right atrial effective refractory period
51 AF: atrial fibrillation
52 APA: action potential amplitude
53 APD50: action potential duration at 50% of repolarization
54 APD90: action potential duration at 90% of repolarization
55 ICa: voltage-dependent calcium current
56 IK1: inward rectifier potassium current
57 IKr: rapidly activating delayed rectifier potassium current
58 IKs: slowly activating delayed rectifier potassium current
59 Ito: transient outward potassium current
60 MABP: mean arterial blood pressure
61 QTc: frequency corrected QT interval
62 RMP: resting membrane potential
63 TdP: Torsade de Pointes polymorphic ventricular tachycardia
64 SEM: standard error of the mean
65 STVQT: short-term variability of the QT interval
66 VF: ventricular fibrillation
67 Vmax: maximum rate of the depolarization
68
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69 Introduction
70 Cardiovascular diseases remain the leading causes of mortality in the developed world. 
71 Approximately 18 million lives are lost annually due to sudden cardiac death, most commonly 
72 caused by severe ventricular arrhythmias degenerating into ventricular fibrillation (VF) 
73 (Shomanova et al., 2020). Following the significant setbacks for pharmacological prevention of 
74 ventricular arrhythmias that were provided by the Cardiac Arrhythmia Suppression Trials (The 
75 Cardiac Arrhythmia Suppression Trial Investigators, 1989; The Cardiac Arrhythmia 
76 Suppression Trial II Investigators, 1992) and the Survival with Oral D-Sotalol trial (Waldo et 
77 al., 1996), where sodium channel blocker Class I/C and potassium channel blocker Class III 
78 compounds - instead of improving clinical outcome - increased mortality in post-myocardial 
79 infarction patients with reduced ejection fraction, the attention shifted towards potential new 
80 antiarrhythmic drugs with more complex ion channel and receptor modulatory effects.
81 Atrial fibrillation (AF), the most prevalent sustained cardiac arrhythmia (Kannel et al., 1982; 
82 Andrade et al., 2014), is associated with significant morbidity and mortality, leading to stroke 
83 (Lip et al., 2011) and heart failure (Larned and Laskar, 2009). The therapy of AF is not optimal, 
84 since pharmacological therapy has limited efficacy (Andrade et al., 2014) and antiarrhythmic 
85 drugs exhibit marked proarrhythmic potential due to their cardiac ventricular 
86 electrophysiological adverse effects (Fenichel et al., 2004), while AF ablation can lead to 
87 complications (Andrade et al., 2014; Aksu et al., 2019; Friedman et al., 2020) and recurrence 
88 of AF following ablation also occurs (Takigawa et al., 2017).
89 One promising approach to safer and more effective pharmacological arrhythmia 
90 management is the use novel compounds that exhibit more complex actions and modulate 
91 several ionic currents. Indeed, amiodarone, a compound affecting a several ionic currents, 
92 remains one of the most effective antiarrhythmic drugs both for the management of AF and 
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93 severe ventricular arrhythmias (Mujovic et al., 2020), however, especially during its chronic 
94 application, it exhibits severe extracardiac adverse effects (Hilleman et al., 1998; Mujović, 
95 2020). Class III antiarrhythmic drugs prolong myocardial repolarization and can effectively 
96 reduce re-entry arrhythmias (Hashimoto et al., 1995; Hohnloser et al., 1995; Fei and Frame, 
97 1996), however, they can also provoke Torsades de Pointes (TdP) tachycardia (Verduyn et al., 
98 1997) and D-sotalol increased mortality in post-myocardial infarction patients (Waldo et al., 
99 1996). Despite its significant QT prolonging effect, amiodarone has a relatively low 
100 torsadogenic adverse effect (Hohnloser et al., 1994; Belardinelli et al., 2003; Thomsen et al., 
101 2004), possibly due to decreased transmural dispersion of repolarization and inhibition of early 
102 afterdepolarization (EAD) formation following amiodarone administration (Sicouri et al., 
103 1997), similarly to Class I/B antiarrhythmic drugs (Shimizu and Antzelevitch, 1997; Assimes 
104 and Malcolm, 1998). Therefore, the development of novel compounds with complex actions 
105 exhibiting combined Class I/B and Class III effects and devoid of severe extracardiac adverse 
106 effects, that are effective against both supraventricular and ventricular arrhythmias, is justified.
107 In this study, a novel compound with complex actions, SZV-270 (Fig. 1), was investigated 
108 regarding its cardiac cellular electrophysiological effects in rabbit and canine atrial and 
109 ventricular preparations. The ventricular antiarrhythmic effects of SZV-270 were also 
110 investigated in rabbits subjected to coronary artery occlusion/reperfusion, and its effects on 
111 atrial fibrillation were tested in dogs with chronic atrial tachypacing-induced atrial remodeling. 
112 Importantly, the potential proarrhythmic adverse effects of SZV-270 were also studied in a 
113 rabbit model developed by our laboratory (Lengyel et al., 2007).
114
115
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116 Materials and methods
117 Ethical issues
118 All animal care and the described experiments complied with the Guide for the Care and Use 
119 of Laboratory Animals (U.S.A. NIH publication No 85-23, revised 1996) and conformed to the 
120 the Directive 2010/63/EU of the European Parliament. The experimental protocols had been 
121 approved by the Ethical Committee for the Protection of Animals in Research of the University 
122 of Szeged, Szeged, Hungary (I-74-18-2016; I-74-15/2017; I-74-24/2017); and also by the 
123 Department of Public Health and Food Chain Safety at the Csongrád County Government 
124 Office (XIII/4227/2016; XIII/3330/2017; XIII/3331/2017).
125
126 Coronary artery occlusion/reperfusion induced ventricular arrhythmias in rabbits
127 Coronary artery occlusion/reperfusion induced arrhythmias were studied in pentobarbitone 
128 (30 mg/kg) anesthetized male rabbits (weighing 2 to 3 kg, n=10/group) as described previously 
129 (Baczko et al., 2000). Briefly, thoracotomy was performed in the fourth intercostal space and 
130 artificial ventilation was performed (Harvard rodent ventilator, model 683, Harvard Apparatus, 
131 South Natick, MA, USA). Following pericardiotomy, a loose loop of 4-0 atraumatic silk 
132 (Ethicon, Edinburgh, UK) was placed around the first branch of the left circumflex coronary 
133 artery, just under its origin. After a 15-min stabilization of blood pressure and heart rate, saline 
134 or 0.3 mg/kg SZV-270 was administered i.v. during a 1 min infusion in a volume of 2 ml/kg, 5 
135 min prior to coronary artery occlusion. Coronary artery occlusion and local myocardial 
136 ischaemia was produced by tightening the loose loop. After 10 min of coronary artery occlusion, 
137 the ligature was released to permit reperfusion for 10 min.
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138 The The ECG was recorded using subcutaneous needle electrodes (lead I, II, III), was 
139 digitized and stored on a computer for off-line analysis using National Instruments data 
140 acquisition hardware (National Instruments, Austin, Texas, USA) and SPEL Advanced 
141 Haemosys software (version 3.2, MDE Heidelberg GmbH, Heidelberg, Germany). The 
142 frequency corrected QT interval (QTc) was calculated by a formula specifically worked out for 
143 anaesthetized rabbits (Batey and Coker, 2002), as follows: QTc = QT – (0.704 * (RR-250)). 
144 Arrhythmias were diagnosed in accordance with the revised Lambeth conventions as ventricular 
145 tachycardia, ventricular fibrillation and other types of arrhythmias including single 
146 extrasystoles, bigeminy, salvos and bradycardia (Curtis et al., 2013).
147 Proarrhythmia studies in rabbits
148 To test whether SZV-270 had proarrhythmic adverse effects, an in vivo rabbit model of 
149 Torsades de Pointes (TdP) was used, developed by our laboratory (Lengyel et al., 2007). Rabbits 
150 of both sexes (weighing 2-3 kg; n=8-11/group) were anaesthetized with thiopentone (50 mg/kg). 
151 A catheter filled with isotonic saline containing 500 IU/mL heparin was inserted into the left 
152 carotid artery for the measurement of arterial blood pressure and the right jugular vein was 
153 cannulated for i.v. drug administration. The animals were allowed to stabilize for 15 min and 
154 baseline measurements were taken. The first group of rabbits received the IKr blocker dofetilide 
155 (25 μg/kg) in a volume of 2 mL/kg in a 5-min infusion. The second group was administered a 
156 combination of the IKs blocker HMR1556 (Gögelein et al., 2000) in 0.1 mg/kg and 25 μg/kg 
157 dofetilide. The third group received a combination of 0.1 mg/kg HMR1556 and 0.3 mg/kg SZV-
158 270. The electrocardiograms were recorded and arrhythmias were diagnosed as described in the 
159 previous section.
160 In order to characterize the instability of beat-to-beat repolarization, Poincaré plots of the 
161 QT intervals were constructed where each QT value was plotted against its former value, using 
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162 31 consecutive QT interval measurements in sinus rhythm at a given time point during the 
163 experiments. The beat-to-beat short-term variability of QT intervals (STVQT) was calculated 
164 using the following formula: STV = ∑|Dn+1-Dn| (30x√2)-1, where D is the duration of the QT 
165 interval. The STVQT has been shown in experimental and clinical settings to be a better predictor 
166 of the development of severe ventricular arrhythmias than QT prolongation (Lengyel et al., 
167 2007; Hinterseer et al., 2010).
168 Atrial fibrillation following chronic atrial tachypacing in conscious dogs
169 Atrial fibrillation was induced in male Beagle dogs (n=6) weighing 12-15 kg as described 
170 previously (Baczko et al., 2014). In brief, two bipolar pacemaker electrodes (Synox SX 53-JBP 
171 and Synox SX 60/15-BP, Biotronik Hungary Ltd., Hungary) were implanted into the right atrial 
172 appendage and the apex of the right ventricle were connected to pacemakers (Logos DS and 
173 Philos S, Biotronik Hungary Ltd., Hungary) placed in subcutaneous pockets in the neck area. 
174 The implantation was followed by radiofrequency catheter ablation of the AV node. Following 
175 a 5-day recovery from surgery, right atrial tachypacing was started at 400 beats/min (ICS 3000 
176 Programmer, Biotronik Hungary Ltd., Hungary), maintained for 6 weeks before the 
177 experiments to induce atrial electrical remodeling (monitored by the measurement of the right 
178 atrial effective refractory period (AERP) every second day). The AERPs were measured at basic 
179 cycle lengths (BCL) of 300 ms with a train of 10 stimuli (S1) followed by an extrastimulus (S2), 
180 with the AERP defined as the longest S1-S2 interval that did not produce a response.
181 On the day of the experiment atrial pacing was stopped, continuous recording of the 
182 electrocardiogram started using precordial leads and the AERP was measured. A control set of 
183 10-second-long rapid atrial bursts (25 times, 800 beats/min, at twice threshold) were performed 
184 to induce atrial fibrillation in conscious dogs preceded by an infusion of vehicle in 15 min. 
185 Following the measurement of AERP, additional sets of atrial bursts were applied subsequent 
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186 to SZV-270 (0.3 mg/kg), or dofetilide (Sigma-Aldrich, 25 g/kg), i.v. administration. At least 
187 5 days were allowed for washout between in vivo experiments with the two compounds. 
188 Intravenous infusions were performed using a programmable infusion pump (Terufusion TE-3, 
189 Terumo Europe, Leuven, Belgium). The ECG was recorded using precordial leads, using SPEL 
190 Advanced Haemosys software (version 3.2, MDE Heidelberg GmbH, Heidelberg, Germany) as 
191 described above. The AERP and the incidence of AF were measured and calculated. 
192 Experiments were performed in unrestraint conscious dogs, therefore any effects of anesthetics 
193 (Freeman et al., 1990; Baczkó et al., 1997) on AERP and AF could be ruled out.
194 Action potential (AP) recordings with the conventional microelectrode technique
195 AP measurements from canine atrial trabeculae
196 Male Beagle dogs (weighing 12-15 kg; n=6) were sedated (xylazine, 1 mg/kg, i.v. and 
197 ketamine, 10 mg/kg, i.v.) and anesthetized (pentobarbital, Sigma-Aldrich, 30 mg/kg i.v.), their 
198 hearts were rapidly removed through right lateral thoracotomy. The hearts were immediately 
199 rinsed in oxygenated modified Locke’s solution containing (in mM): NaCl 128.3, KCl 4, CaCl2 
200 1.8, MgCl2 0.42, NaHCO3 21.4, and glucose 10. The pH of the solution was set between 7.35 
201 and 7.4 when saturated with the mixture of 95% oxygen and 5% CO2 at 37 ºC. Isolated right 
202 atrial trabeculae were obtained, individually mounted in a tissue chamber and stimulated as 
203 decribed previously (Juhász et al., 2018). The maximal rate of depolarization (Vmax), maximum 
204 diastolic potential, action potential amplitude, and action potential duration measured at 90% 
205 of repolarization (APD90) were evaluated off-line, applying stimulation with a constant basic 
206 cycle length (BCL) of 500 ms.
207 AP measurements from canine and rabbit right ventricular papillary muscle and in canine 
208 Purkinje fibers
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209 Male Beagle dogs (weighing 12-15 kg; n=7) and white rabbits (weighing 2-3 kg; n=6) were 
210 used for the experiments. Right ventricular papillary muscle tips were obtained, mounted and 
211 stimulated using the conventional microelectrode technique as described previously (Jost et al., 
212 2013; Kohajda et al., 2016). The preparations were stimulated (HSE stimulator type 215/II) 
213 initially at a constant cycle length of 500 ms (rabbit papillary muscle and canine Purkinje fibers) 
214 or 1000 ms (canine papillary muscle), with rectangular constant current pulses 2 ms in duration. 
215 The current pulses were isolated from ground and delivered through bipolar platinum 
216 electrodes. Transmembrane potentials were recorded with the use of conventional 5–20 M, 3 
217 M KCl-filled microelectrodes connected to the input of a high-impedance electrometer 
218 (Biologic Amplifier VF 102, Claix, France). The first derivative of transmembrane potential 
219 (dV/dtmax) was obtained electronically with a Biologic DV-140 (Claix, France) differentiator. 
220 At least 1 h was allowed for each preparation to equilibrate during continuous superfusion with 
221 modified Locke’s solution, warmed to 37˚C before the experimental measurements 
222 commenced. The following types of stimulation in the course of the experiments were applied: 
223 stimulation with a constant cycle length of 1000 or 500 ms (1 or 2 Hz); stimulation with different 
224 constant cycle lengths ranging from 300 to 5000 ms taking the measurements after the 25th beat. 
225 The preparations were then superfused with the solution containing 1 μM SZV-270 for 40–60 
226 min before the pacing protocol was repeated and the parameters were measured again, then 
227 superfusion continued with 5 μM SZV-270 for another 40-60 min and measurements were 
228 repeated. Efforts were made to maintain the same impalement throughout each experiment. In 
229 case an impalement became dislodged, however, adjustment was performed and the experiment 
230 continued if AP characteristics of the re-established impalement deviated less than 5% from the 
231 previous measurement.
232
233 Whole cell patch-clamp studies
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234 Isolated ventricular cardiomyocytes were obtained from male rabbits (weighing 2-3 kg) by 
235 enzymatic dissociation as described previously (Major et al., 2016). A drop of cell suspension 
236 was placed into a transparent recording chamber mounted on the stage of an inverted 
237 microscope (Olympus IX51, Olympus, Tokyo, Japan), and myocytes were allowed to settle and 
238 adhere to the bottom of the chamber for at least 5 minutes before superfusion was initiated. 
239 HEPES buffered Tyrode's solution was used as the normal superfusate. This solution contained 
240 (in mM): NaCl 144, NaH2PO4 0.4, KCl 4.0, CaCl2 1.8, MgSO4 0.53, Glucose 5.5, and HEPES 
241 5.0 at pH of 7.4. Patch clamp micropipettes were made from borosilicate glass capillaries using 
242 a P-97 Flaming/Brown micropipette puller (Sutter Co, Novato, CA, USA). The electrodes had 
243 1.5-2.5 M resistances when filled with pipette solution that contained (in mM): KOH 110, 
244 KCl 40, K2ATP 5, MgCl2 5, EGTA 5, GTP 0.1 and HEPES 10, during K+ current measurements. 
245 Aspartic acid was used to adjust the pH of the pipette solution to 7.2. The L-type calcium current 
246 (ICa,L) was recorded in HEPES-buffered Tyrode’s solution supplemented with 3 mM 4-
247 aminopyridine. A special pipette solution was used containing (in mM: KOH 40, KCl 110, 
248 TEACl 20, MgATP 5, EGTA 10, HEPES 10 and GTP 0.25, pH was adjusted to 7.2 by KOH.
249 Ionic membrane currents were recorded with the Axopatch 200B patch-clamp amplifier 
250 (Molecular Devices, Sunnyvale, CA, USA) using the whole cell configuration of the patch 
251 clamp technique. Membrane currents were digitized and recorded under software control 
252 (Digidata 1440A, pClamp 10, Molecular Devices, Sunnyvale, CA, USA) after low-pass 
253 filtering at 1 kHz. The inward rectifier (IK1), transient outward (Ito), rapid (IKr) delayed rectifier 
254 potassium currents were recorded in rabbit ventricular myocytes. 1 µM nisoldipine was 
255 included in the bath solution to block ICa,L. When IKr was recorded, IKs was inhibited by using 
256 the selective IKs blocker HMR1556 (0.5 µM). All experiments were performed at 37 °C.
257 Statistical analysis
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258 The incidence of arrhythmias was calculated and compared by using the 2 method. All other 
259 data are expressed as mean ± SEM. Statistical analysis was performed using ORIGIN 8.1 
260 (Microcal Software, Northampton, MA, USA). Differences between means were compared by 
261 ANOVA followed by Student’s t-test (paired or unpaired, as appropriate). Data were considered 
262 as statistically significant when p<0.05.
263
264
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265 Results
266 Effects of SZV-270 on blood pressure and ECG parameters in anesthetized rabbits
267 There were no significant differences in the mean arterial blood pressures (MABP) between 
268 the control and the SZV-270 (0.3 mg/kg, i.v.) treated rabbits 5 min following SZV-270 
269 administration (80 ± 4.9 vs. 77 ± 3.9 mmHg, respectively, p>0.05). Coronary artery occlusion 
270 led to a significant reduction in MABP in both groups (59 ± 5.3 vs 80 ± 4.9 mmHg in controls 
271 and 56 ± 3.8 vs 77 ± 3.9 in the SZV-270 group, all p<0.05, measured at 1 min following 
272 occlusion). SZV-270 administration did not change heart rate in anesthetized rabbits (251 ± 
273 10.1 after infusion vs 258 ± 6.5 beats/min before infusion, p>0.05). Coronary artery occlusion 
274 and reperfusion did not change heart rate significantly in any of the groups. SZV-270 
275 administration moderately but significantly prolonged the QTc interval in these animals (172 ± 
276 3.3 vs 165 ± 4.4 ms before infusion, p<0.05). There were no significant changes in QTc intervals 
277 during reperfusion. The PQ interval did not change following SZV-270 infusion (56 ± 1.3 vs 
278 54 ± 1.8 ms before infusion, p>0.05). The QRS interval was widened by SZV-270 (35 ± 1.9 ms 
279 at baseline vs 44 ± 1.8 following SZV-270 infusion, p<0.05).
280 Effects of SZV-270 on coronary artery occlusion/reperfusion induced ventricular arrhythmias 
281 in anesthetized rabbits
282 No arrhythmias were observed during the infusion of SZV-270 or vehicle, or following 
283 infusion preceding coronary artery occlusion. There were no differences between the control 
284 group and the SZV-270 treated group regarding the incidence of VT (40% in controls and 20% 
285 in the SZV-270 group, p>0.05) or VF (30% in controls and 10% in the SZV-270 group, p>0.05) 
286 during 10 min of coronary artery occlusion.
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287 Arrhythmias induced by reperfusion of the occluded coronary artery occurred within 10-30 s 
288 following the ligature release. Importantly, 0.3 mg/kg SZV-270 pretreatment significantly 
289 reduced the incidence of reperfusion-induced VF (20% in SZV-270 treated group vs 80% in 
290 controls, p<0.05). The incidence of VT and Salvos were not decreased significantly (60% in the 
291 SZV-270 group vs 90% in controls for both arrhythmia types, all p>0.05).
292 Effects of SZV-270 in an anesthetized rabbit proarrhythmia model
293 Antiarrhythmic drugs that prolong repolarization can provoke Torsade de Pointes (TdP) 
294 polymorphic ventricular arrhythmias. Therefore, the proarrhythmic potency of SZV-270 was 
295 evaluated and compared to that of the pure Class III compound, dofetilide, using our previously 
296 developed anesthetized rabbit proarrhythmia model, characterized by the pharmacological 
297 reduction of repolarization reserve (Lengyel et al., 2007). In anesthetized rabbits, repolarization 
298 reserve was impaired by the i.v. administration of the selective IKs blocker HMR1556 (0.1 
299 mg/kg) (Gögelein et al., 2000), followed by either the i.v. infusion of the selective IKr blocker 
300 dofetilide (25 µg/kg) or SZV-270 (0.3 mg/kg). A group of rabbits received dofetilide on its own 
301 to allow comparison of the effects of the IKr blocker alone to the rest of the experimental groups.
302 The IKs blocker HMR1556 did not change the QRS intervals (33 ± 0.9 vs 33 ± 0.6 ms at 
303 baseline, p>0.05) and did not influence heart rate (269 ± 5.2 vs 271 ± 9.8 beats/min at baseline, 
304 p>0.05). Following HMR1556 infusion, SZV-270 (0.3 mg/kg) administration significantly 
305 widened the QRS interval, similarly to the results in our rabbits in the previous set of 
306 experiments subjected to coronary artery occlusion/reperfusion (see above). (Fig. 2A). The 
307 combination of HMR1556 and SZV-270 did not change the PQ interval in anesthetized rabbits 
308 (63 ± 1.3 in control vs 62 ± 1.4 following HMR1556 and 62 ± 1.6 ms following 
309 HMR1556+SZV-270, all p>0.05). SZV-270 decreased heart rate following HMR1556 
310 administration (230 ± 6.8 vs 269 ± 5.2 beats/min, p<0.05). The IKs blocker HMR1556 did not 
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311 increase the QTc interval (Fig. 2B). Dofetilide, alone and in combination with HMR1556, and 
312 SZV-270 in combination with HMR1556 significantly prolonged the QTc interval (Fig. 2B).
313 A novel, more reliable ECG biomarker for the prediction of drug-induced ventricular 
314 arrhythmias is short-term variability of the QT interval (STVQT). STVQT was moderately 
315 increased after dofetilide administration and markedly increased after the combined 
316 administration of HMR1556 and dofetilide (Fig. 2C). These changes were in good correlation 
317 with the increase in the incidence of TdP in these groups (Fig. 2D). Importantly, following 
318 impairment of repolarization reserve with the IKs blocker HMR1556, SZV-270 administration 
319 did not increase STVQT (Fig. 2C) nor did it induce any TdP in anesthetized rabbits (Fig. 2D), 
320 suggesting no proarrhythmic potential of SZV-270 in this model.
321 Effects of SZV-270 and dofetilide on burst-induced atrial fibrillation in conscious dogs
322 Before starting the chronic rapid atrial pacing at 400 beats/min in conscious dogs, the right 
323 atrial effective refractory period (AERP) values in these animals were 128 ± 3.2 ms (n=6, at 
324 basic cycle length of 300 ms). The AERP significantly decreased to 88 ± 2.8 ms following 6 
325 weeks of rapid right atrial pacing, indicating marked electrical remodeling of the right atrium. 
326 In all dogs, the effects of SZV-270 on AERP and incidence of AF were compared to that of the 
327 IKr blocker dofetilide. As Figure 3 illustrates, both SZV-270 and dofetilide significantly 
328 prolonged AERP and markedly reduced the incidence of AF in unrestraint conscious dogs.
329 Effects of SZV-270 on action potentials in rabbit and canine right ventricular papillary muscle
330 In the following sets of in vitro experiments, the possible mechanisms responsible for the atrial 
331 and ventricular antiarrhythmic effects of SZV-270 were investigated. First, the effects of SZV-
332 270 (1 and 5 µM) were studied on different action potential parameters in rabbit and canine 
333 right ventricular papillary muscle preparations using the conventional microelectrode 
334 technique. As Table 1 and 2 illustrate, SZV-270 at 1 Hz stimulation frequency did not alter 
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335 resting membrane potential (RMP), maximum rate of depolarization (Vmax) and action potential 
336 amplitude (APA) in rabbit and dog papillary muscle. However, SZV-270 exerted Class III 
337 antiarrhythmic effects by prolonging the action potential duration at 50%, 75% and 90% of 
338 repolarization (APD50, APD75 and APD90) and the effective refractory period in a concentration 
339 dependent manner in both species (Fig. 4A, Fig. 5A, Table 1 and 2).  The cycle length 
340 dependent effects of SZV-270 (1 and 5 µM) were also studied in rabbit right ventricular 
341 papillary muscle preparations (Fig. 4B and C). In the higher applied concentration, SZV-270 
342 exerted Class I/B antiarrhythmic effect in both species: it significantly decreased Vmax at cycle 
343 lengths shorter than 1000 ms (Fig. 4B and Fig. 5B).
344 Effects of SZV-270 on action potentials in canine Purkinje fibers
345 SZV-270 did not alter the RMP or the APA in dog Purkinje fibers (Table 4). SZV-270 exerted 
346 more complex effects on action potential duration in Purkinje fibers compared to papillary 
347 muscle preparations. As shown in (Table 4), at 2 Hz stimulation frequency the compound 
348 significantly prolonged the APD75 and APD90, however, the APD prolongation was smaller 
349 following the application of the larger concentration than that observed after the application of 
350 the smaller concentration. The larger concentration significantly shortened APD50. SZV-270 
351 significantly reduced Vmax in a concentration dependent manner (Table 4).
352 Effects of SZV-270 on action potentials in canine atrial trabeculae
353 In the next set of experiments, the effects of SZV-270 (1 and 5 µM) on atrial action potentials 
354 were investigated in isolated canine atrial trabeculae. SZV-270 did not change the RMP, Vmax 
355 and APA at 2 Hz stimulation frequency in dog atrial preparations (Table 3). Importantly, SZV-
356 270 significantly prolonged atrial action potentials (Fig. 6A), APD50, APD75 and APD90 in a 
357 concentration dependent manner (Table 3). These effects can, at least in part, be responsible 
358 for the observed atrial antiarrhythmic effects of SZV-270 in our dog AF model.
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359 Effects of SZV-270 on various transmembrane ionic currents in isolated rabbit ventricular 
360 myocytes
361 To elucidate the cellular mechanisms that can be responsible for the observed in vivo and in 
362 vitro effects of SZV-270, rabbit right ventricular myocytes were isolated and the effects of the 
363 compound were studied on IKr, IK1, Ito and ICa,L using the patch-clamp technique in the whole 
364 cell configuration. As Figure 7 shows, SZV-270 significantly inhibited IKr in relatively low, 
365 100 and 500 nM concentrations. This result is in agreement with the APD prolonging and QTc 
366 lengthening effect of the compound. SZV-270 did not influence the other transmembrane 
367 currents, IK1 (Fig. 8A), Ito (Fig. 8B) and ICa,L (Fig. 9), even at the high concentration of 10 µM.
368
369 Discussion
370 In this study, the cardiac cellular electrophysiological and in vivo antiarrhythmic effects of 
371 SZV-270, a novel compound with a structure that features Class I/B and Class III structural 
372 elements (of D-sotalol and mexiletine), were investigated in dogs and rabbits, two species used 
373 frequently in arrhythmia research. Importantly, the proarrhythmic potency of SZV-270 was also 
374 assessed in a rabbit proarrhythmia model based on pharmacological impairment of 
375 repolarization reserve.
376 In a rabbit model of coronary artery occlusion/reperfusion, SZV-270 significantly reduced the 
377 the number of animals that died due to irreversible ventricular fibrillation during the reperfusion 
378 period. In this model, SZV-270 did not change heart rate and the PQ interval duration, however, 
379 it significantly widened QRS interval and prolonged the frequency corrected QT interval. To 
380 elucidate the mechanisms underlying the ventricular antiarrhythmic effects of SZV-270, action 
381 potential measurements were performed in rabbit and dog right ventricular papillary muscle 
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382 preparations, and several ionic currents were also measured in isolated rabbit right ventricular 
383 cardiomyocytes. In agreement with the observed QTc prolonging effect of SZV-270 (Fig. 2B), 
384 the compound lengthened the effective refractory period, APD50, APD75 and APD90 in a 
385 concentration dependent manner in ventricular preparations in both species (Table 1 and 2). 
386 Furthermore, SZV-270 significantly inhibited the IKr tail current at relatively low concentrations 
387 of 100 and 500 nM (Fig. 7). These Class III antiarrhythmic effects were supplemented by Class 
388 I/B effects of SZV-270 in the present study. In right ventricular preparations isolated from dogs 
389 and rabbits, the larger investigated concentration of SZV-270 significantly reduced Vmax at 
390 stimulation cycle lengths shorter than 1000 ms (Figs. 4B and 5B). In addition, the larger 
391 concentration of SZV-270 prolonged APD90 in a lesser degree and significantly shortened 
392 APD50 (depressed the plateau phase) in dog Purkinje fibers (Table 4). These effects can 
393 decrease repolarization heterogeneity in the ventricle, resembling a similar effect of amiodarone 
394 (Papp et al., 1996). Even high concentrations of SZV-270 did not affect IK1, Ito and ICa,L in rabbit 
395 right ventricular cardiomyocytes (Figs. 8 and 9). Indeed, the PQ interval was not altered by 
396 SZV-270 infusion in anesthetized rabbits in this study, further supporting the lack of effect of 
397 the compound on ICa,L.
398 Based on the results of this study, SZV-270 exhibits combined Class I/B and Class III 
399 antiarrhythmic actions. What makes this combination beneficial? Class III drugs prolong 
400 repolarization and the effective refractory period and are especially effective against re-entry 
401 arrhythmias (Lynch et al., 1985; Hohnloser et al., 1995; Fei and Frame, 1996). However, Class 
402 III compounds possess marked proarrhythmic activity: they promote EAD formation and 
403 subsequent development of TdP polymorphic ventricular tachycardia (Buchanan et al., 1993; 
404 Vos et al., 1995; Gottlieb et al., 1997). Drugs with ClassI/B actions, however, can reduce EAD 
405 formation (Papp et al., 1996; Sicouri et al., 1997) and have been shown to suppress TdP induced 
406 by pure Class III agents (Shimizu and Antzelevitch, 1997; Assimes and Malcolm, 1998). Also, 
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407 the combination of the Class I/B drug mexiletine and the Class III compound sotalol prevented 
408 ventricular tachyarrhythmias in dogs with myocardial infarction (Chezalviel et al., 1993). 
409 Luderitz et al. also suggested that the combination of mexiletine and sotalol was able to suppress 
410 ventricular arrhythmias more effectively than either compound alone (Luderitz et al., 1991). 
411 These results strongly suggest that a compound with combined Class I/B and III effects can 
412 prevent re-entry arrhythmias with reduced risk of provoking TdP arrhythmia.
413 Compounds that prolong cardiac ventricular repolarization, manifested as QT lengthening on 
414 the ECG, as mentioned above, have been associated with severe proarrhythmic adverse effects 
415 (Haverkamp et al., 2000; Redfern et al., 2003). However, QT prolongation does not necessarily 
416 cause TdP (Hondeghem et al., 2001; Milberg et al., 2002; Thomsen et al., 2004;). In this regard, 
417 several biomarkers have been proposed for improved prediction of proarrhythmic risk. Among 
418 those, the use of the short-term variability of the QT interval, characterizing the beat-to-beat 
419 variability of the QT interval and therefore the temporal variability of repolarization, has been 
420 suggested (for a review see Varkevisser et al., 2012). Indeed, both animal experimental 
421 (Thomsen et al., 2004; Lengyel et al., 2007) and clinical studies (Hinterseer et al., 2009; 
422 Hinterseer et al., 2010) have shown that the STVQT was a superior biomarker for severe 
423 ventricular arrhythmia predictor compared to QT prolongation and other conventional ECG 
424 parameters. In the present study, SZV-270 exerted atrial and ventricular antiarrhythmic effects, 
425 due to, at least in part, to its IKr blocking, APD and QT prolonging properties. Therefore, we 
426 studied its proarrhythmic potency in a rabbit proarrhythmia model characterized by 
427 pharmacological impairment of repolarization reserve (Lengyel et al., 2007). The concept of 
428 repolarization reserve (Roden 1998) suggests that cardiac repolarization is redundant: inhibition 
429 or impairment of one of the repolarizing potassium currents does not lead to marked 
430 repolarization prolongation, since other currents can compensate for the lost repolarizing 
431 function (Varro et al., 2000; Roden 2006; Varro and Baczko 2011). In case, however, 
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432 repolarization reserve is attenuated by the inhibition or loss of function of IKs, a key current for 
433 repolarization reserve (Jost et al., 2005), even a mild inhibition of IKr and other repolarizing 
434 currents can lead to severe ventricular arrhythmia development (Lengyel et al., 2007; Varro and 
435 Baczko, 2001). In the present study, we found no proarrhythmic adverse effects of SZV-270. 
436 Following the impairment of repolarization reserve by the administration of the selective IKs 
437 blocker HMR1556 (Gögelein et al, 2000), SZV-270 did not increase STVQT and did not induce 
438 any TdP in anesthetized rabbits. In contrast, the selective IKr blocker dofetilide significantly 
439 increased STVQT and provoked TdP in 85% of rabbits following IKs inhibition (Fig. 2D).
440 In a conscious dog model of atrial fibrillation that is based on chronic right atrial tachypacing-
441 induced atrial electrical remodeling (Morillo et al., 1995), SZV-270 significantly reduced the 
442 incidence of burst-induced AF and prolonged the AERP (Fig. 3). In canine right atrial 
443 trabeculae, SZV-270 prolonged the APD50, APD75 and APD90 in a concentration dependent 
444 manner (Table 3). The effects of SZV-270 on AF in this model were comparable to those of 
445 the selective IKr blocker dofetilide, which is known as an effective compound for rhythm control 
446 in AF (Kirchhof 2016; Piccini and Fauchier 2016). Dofetilide also reduced AF incidence and 
447 increased AERP in the present study, and was shown to prolong atrial APD in atrial trabeculae 
448 isolated from dogs with chronic tachypacing induced atrial remodeling (Juhász et al., 2018). 
449 The beneficial effects of dofetilide in AF were attributed to its atrial repolarization and AERP 
450 prolonging effects (Allessie et al., 2001; Pedersen et al., 2001). The AF incidence reducing 
451 effects of SZV-270 is also probably due to its atrial APD prolonging effects in this study.
452 Conclusions
453 In conclusion, SZV-270 protected against coronary artery occlusion/reperfusion-induced 
454 ventricular arrhythmias in rabbits. SZV-270 significantly reduced the incidence of atrial 
455 fibrillation and prolonged atrial effective refractory period in a conscious dog model of atrial 
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456 fibrillation. Our cellular electrophysiological investigations revealed that SZV-270 exerted its 
457 ventricular and atrial antiarrhythmic effects via combined Class I/B and Class III actions. 
458 Importantly, despite its IKr blocking and QT prolonging properties, SZV-270 did not provoke 
459 TdP arrhythmia in an anesthetized rabbit proarrhythmia model.
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RMP (mV) -86.3 ± 1.8 -84.2 ± 1.2 -85.2 ± 1.4
APA (mV) 115.7 ± 1.8 112.8 ± 3.3 113.5 ± 2.5
APD10 (ms) 54.8 ± 7.2 49.6 ± 7.4 50.8 ± 9.1
APD25 (ms) 105.2 ± 11.5 108.2 ± 14.6 114.5 ±16.2 
APD50 (ms) 152.3 ± 15.4 178.7 ± 18.9 * 221.2 ± 23.9*
APD75 (ms) 174.3 ± 15.6 209.0 ± 18.6 * 263.7 ± 23.9*
APD90 (ms) 183.3 ±15.4 219.3 ± 18.5 * 274.5 ± 23.7*
Vmax (V/s) 229.8 ± 24.3 231.2 ± 23.2 241.0 ± 22.1
ERP (ms) 174.7 ± 14.7 223.8 ± 20.4 * 277.5 ± 27.5*
468
469 Table 1. Effect of SZV-270 (1 and 5 µM) on the action potential in rabbit right ventricular 
470 papillary muscle preparations (n=6). Stimulation frequency = 1 Hz; RMP = resting membrane 
471 potential; APA = action potential amplitude; APD10–25–50–75–90 = action potential duration at 10, 
472 25, 50, 75 and 90% of repolarisation; Vmax = maximal rate of depolarization; ERP = effective 
473 refractory period. Results are expressed as means ± SEM; *p<0.05.
474
475







RMP (mV) -84.9 ± 1.0 -85.4 ± 1.0 -83.9 ± 1.1
APA (mV) 105.4 ± 1.3 107.3 ± 1.3* 106.0 ± 2.4
APD10 (ms) 60.9 ± 13.3 66.3 ± 14.2 58.9 ±16.7
APD25 (ms) 133.0 ± 6.9 143.9 ± 8.0* 149.4 ± 7.7
APD50 (ms) 180.0 ± 6.8 198.3 ± 9.9* 208.0 ±11.4
APD75 (ms) 201.6 ± 7.5 222.6 ± 11.0* 240.7 ± 10.4*
APD90 (ms) 211.4 ± 7.9 233.6 ± 11.2* 251.7 ± 10.6*
Vmax (V/s) 208.0 ± 8.9 220.6 ± 13.0 212.0 ± 12.7
ERP (ms) 223.4 ± 8.3 250.0 ± 14.1* 263.4 ± 13.1*
477
478 Table 2. Effect of SZV-270 (1 and 5 µM) on the action potential in canine right ventricular 
479 papillary muscle preparations (n=7). Stimulation frequency = 1 Hz; RMP = resting membrane 
480 potential; APA = action potential amplitude; APD10–25–50–75–90 = action potential duration at 10, 
481 25, 50, 75 and 90% of repolarisation; Vmax = maximal rate of depolarization; ERP = effective 
482 refractory period. Results are expressed as means ± SEM; *p<0.05.
483
484







RMP (mV) -85.7 ± 1.2 -85.2 ± 1.6 -85.5 ± 1.1
APA (mV) 109.0 ± 1.0 109.3 ± 1.6 111.5 ± 2.5
APD10 (ms) 9.0 ± 0.7 9.2 ± 0.5 9.5 ± 0.8
APD25 (ms) 43.8 ± 5.1 46.6 ± 4.6 47.4 ± 4.2
APD50 (ms) 74.0 ± 5.8 81.8 ± 8.0* 83.8 ± 6.6*
APD75 (ms) 100.2 ± 4.8 115.0 ± 8.8* 120.5 ± 8.0*
APD90 (ms) 130.8 ± 4.1 156.0 ± 9.6* 165.0 ± 9.4*
Vmax (V/s) 299.8 ± 38.8 343.0 ± 37.8 347.2 ± 45.8
486
487 Table 3. Effect of SZV-270 (1 and 5 µM) on the action potential in canine atrial trabecular 
488 preparations (n=6). Stimulation frequency = 2 Hz; RMP = resting membrane potential; APA = 
489 action potential amplitude; APD10–25–50–75–90 = action potential duration at 10, 25, 50, 75 and 
490 90% of repolarisation; Vmax = maximal rate of depolarization. Results are expressed as means 
491 ± SEM; *p<0.05.
492






RMP (mV) -89.3 ± 0.8 -90.2 ± 0.6 -89.2 ± 0.6
APA (mV) 125.0 ± 1.9 127.2 ±1.5 123.7 ± 1.5
APD10 (ms) 1.77 ± 0.15 1.77 ± 0.17 1.73 ± 0.21
APD25 (ms) 32.6 ± 9.6 30.5 ± 10.0 24.6 ± 7.2
APD50 (ms) 174.7 ±11.1 186.8 ± 13.9 144.2 ± 12.1*
APD75 (ms) 229.3 ± 6.3 271.5 ± 9.6* 245.5 ± 7.1*
APD90 (ms) 250.0 ± 6.3 301.0 ± 10.2* 285.0 ± 9.1*
Vmax (V/s) 730.8 ± 67.6 704.7 ± 64.3* 684.8 ± 43.4*
493
494 Table 4. Effect of SZV-270 (1 and 5 µM) on the action potential in canine Purkinje fibers (n=6). 
495 Stimulation frequency = 2 Hz; RMP = resting membrane potential; APA = action potential 
496 amplitude; APD10–25–50–75–90 = action potential duration at 10, 25, 50, 75 and 90% of 
497 repolarisation; Vmax = maximal rate of depolarization; *p<0.05
498
499
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500 Figure legends
501 Fig. 1. Chemical structure of SZV-270.
502
503 Fig. 2. The effects of the IKs blocker HMR1556 (0.1 mg/kg, i.v.), the IKr blocker dofetilide (25 
504 µg/kg, i.v.) and SZV-270 (0.3 mg/kg, i.v.) on different ECG parameters and the incidence of 
505 Torsades de Pointes (TdP) arrhythmia in an anesthetized rabbit proarrhythmia model. (A) Only 
506 SZV-270 widened the QRS interval, while (B) the frequency corrected QT interval (QTc) was 
507 prolonged by dofetilide, the combination of HMR1556+dofetilide and HMR1556+SZV270. 
508 (C) Despite prolonging QTc, the combination of HMR1556+SZV270 did not increase the short-
509 term variability of the QT interval (STVQT), a surrogate biomarker for the prediction of 
510 ventricular arrhythmias. (D) In parallel with a markedly and significantly increased STVQT, 
511 only the combination of HMR1556+dofetilide led to a high incidence of TdP. SZV-270 did not 
512 show any proarrhythmic activity in this model with impaired repolarization reserve. Values are 
513 mean ± SEM. #p<0.05 vs. baseline values within the same group; *p<0.05 vs. dofetilide group; 
514 n=8-11 rabbits/group.
515
516 Fig. 3. Effect of the selective IKr blocker dofetilide (25 g/kg, i.v.) and SZV-270 (0.3 mg/kg, 
517 i.v.) on atrial fibrillation in conscious dogs with atrial tachypacing-induced electrical atrial 
518 remodeling. (A) Both dofetilide and SZV-270 significantly increased right atrial effective 
519 refractory period (AERP). (B) Both dofetilide and SZV-270 significantly reduced the incidence 
520 of atrial fibrillation (AF). AERP was measured at basic cycle length of 300 ms. Values are mean 
521 ± SEM; n=4-6 animals/group; *p<0.05 vs control values.
522
523 Fig. 4. Effect of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at different 
524 stimulation cycle lengths recorded from rabbit right ventricular papillary muscle preparations. 
525 (A) SZV-270 prolonged the action potential in rabbit right ventricular papillary muscle. (B) 
526 SZV-270 (5 µM) significantly reduced Vmax at 300 ms cycle length, (C) and both concentrations 
527 significantly prolonged APD90 at cycle lengths shorter than 3000 ms in these preparations. 
528 Values are means ± SEM. n=6, *p<0.05 vs. control values.
529
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530 Fig. 5. Effect of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at different 
531 stimulation cycle lengths recorded from dog right ventricular papillary muscle preparations. (A) 
532 SZV-270 prolonged the action potential in canine right ventricular papillary muscle. (B) SZV-
533 270 (5 µM) significantly reduced Vmax at 300 ms cycle length, (C) and both concentrations 
534 significantly prolonged APD90 in these preparations. Values are means ± SEM. n=6, *p<0.05 
535 vs. control values.
536
537 Fig. 6. The effects of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at 
538 different stimulation cycle lengths recorded from isolated canine right atrial trabeculae. (A) 
539 SZV-270 prolonged the action potential in dog atrial trabeculae. (B) SZV-270 did not 
540 significantly alter Vmax, however, (C) significantly prolonged APD90 in these preparations. 
541 Values are means ± SEM. n=6, *p<0.05 vs. control values.
542
543 Fig. 7. The effect of SZV-270 on the rapid component of the delayed rectifier potassium current 
544 (IKr). SZV-270 inhibited the IKr tail current in a concentration dependent manner (panel A: 
545 effects of 100 nM, panel B: effects of 500 nM SZV-270). Left subpanels show original current 
546 traces in control conditions and following application of 100 and 500 nM SZV-270. Graphs on 
547 the right show the respective current-voltage relationships. Values are means ± SEM. n=3-5, 
548 *p<0.05 vs corresponding data point in control conditions.
549
550 Fig. 8. SZV-270 did not influence (A) IK1 or (B) Ito even at the high concentration of 10 µM in 
551 isolated rabbit right ventricular cardiomyocytes. Left panels depict original current traces 
552 recorded in control conditions and in the presence of 10 µM SZV-270. Right panels show the 
553 current-voltage relationships. Values are means ± SEM. n=5-6, all p>0.05.
554
555 Fig. 9. SZV-270 did not influence ICa,L even at the high concentration of 10 µM in isolated 
556 rabbit right ventricular cardiomyocytes. Left panels depict original current traces recorded in 
557 control conditions, in the presence of 10 µM SZV-270 and following washout. Right panel 
558 shows the current-voltage relationship. Values are means ± SEM. n=4, all p>0.05.
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Fig. 1. Chemical structure of SZV-270. 
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Fig. 2. The effects of the IKs blocker HMR1556 (0.1 mg/kg, i.v.), the IKr blocker dofetilide (25 μg/kg, i.v.) 
and SZV-270 (0.3 mg/kg, i.v.) on different ECG parameters and the incidence of Torsades de Pointes (TdP) 
arrhythmia in an anesthetized rabbit proarrhythmia model. (A) Only SZV-270 widened the QRS interval, 
while (B) the frequency corrected QT interval (QTc) was prolonged by dofetilide, the combination of 
HMR1556+dofetilide and HMR1556+SZV270. (C) Despite prolonging QTc, the combination of 
HMR1556+SZV270 did not increase the short-term variability of the QT interval (STVQT), a surrogate 
biomarker for the prediction of ventricular arrhythmias. (D) In parallel with a markedly and significantly 
increased STVQT, only the combination of HMR1556+dofetilide led to a high incidence of TdP. SZV-270 did 
not show any proarrhythmic activity in this model with impaired repolarization reserve. Values are mean ± 
SEM. #p<0.05 vs. baseline values within the same group; *p<0.05 vs. dofetilide group; n=8-11 
rabbits/group. 
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Fig. 3. Effect of the selective IKr blocker dofetilide (25 μg/kg, i.v.) and SZV-270 (0.3 mg/kg, i.v.) on atrial 
fibrillation in conscious dogs with atrial tachypacing-induced electrical atrial remodeling. (A) Both dofetilide 
and SZV-270 significantly increased right atrial effective refractory period (AERP). (B) Both dofetilide and 
SZV-270 significantly reduced the incidence of atrial fibrillation (AF). AERP was measured at basic cycle 
length of 300 ms. Values are mean ± SEM; n=4-6 animals/group; *p<0.05 vs control values. 
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Fig. 4. Effect of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at different stimulation 
cycle lengths recorded from rabbit right ventricular papillary muscle preparations. (A) SZV-270 prolonged 
the action potential in rabbit right ventricular papillary muscle. (B) SZV-270 (5 µM) significantly reduced 
Vmax at 300 ms cycle length, (C) and both concentrations significantly prolonged APD90 at cycle lengths 
shorter than 3000 ms in these preparations. Values are means ± SEM. n=6, *p<0.05 vs. control values. 
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Fig. 5. Effect of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at different stimulation 
cycle lengths recorded from dog right ventricular papillary muscle preparations. (A) SZV-270 prolonged the 
action potential in canine right ventricular papillary muscle. (B) SZV-270 (5 µM) significantly reduced Vmax 
at 300 ms cycle length, (C) and both concentrations significantly prolonged APD90 in these preparations. 
Values are means ± SEM. n=6, *p<0.05 vs. control values. 
266x465mm (300 x 300 DPI) 
Page 41 of 45
 
Fig. 6. The effects of SZV-270 (1 and 5 µM) on the action potential, on Vmax and APD90 at different 
stimulation cycle lengths recorded from isolated canine right atrial trabeculae. (A) SZV-270 prolonged the 
action potential in dog atrial trabeculae. (B) SZV-270 did not significantly alter Vmax, however, (C) 
significantly prolonged APD90 in these preparations. Values are means ± SEM. n=6, *p<0.05 vs. control 
values. 
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Fig. 7. The effect of SZV-270 on the rapid component of the delayed rectifier potassium current (IKr). SZV-
270 inhibited the IKr tail current in a concentration dependent manner (panel A: effects of 100 nM, panel B: 
effects of 500 nM SZV-270). Left subpanels show original current traces in control conditions and following 
application of 100 and 500 nM SZV-270. Graphs on the right show the respective current-voltage 
relationships. Values are means ± SEM. n=3-5, *p<0.05 vs corresponding data point in control conditions. 
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Fig. 8. SZV-270 did not influence (A) IK1 or (B) Ito even at the high concentration of 10 µM in isolated rabbit 
right ventricular cardiomyocytes. Left panels depict original current traces recorded in control conditions and 
in the presence of 10 µM SZV-270. Right panels show the current-voltage relationships. Values are means ± 
SEM. n=5-6, all p>0.05. 
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Fig. 9. SZV-270 did not influence ICa,L even at the high concentration of 10 µM in isolated rabbit right 
ventricular cardiomyocytes. Left panels depict original current traces recorded in control conditions, in the 
presence of 10 µM SZV-270 and following washout. Right panel shows the current-voltage relationship. 
Values are means ± SEM. n=4, all p>0.05. 
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